PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.79%
Both companies show declining cash positions (-35.79% vs CRVO's -23.62%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-35.79%
Cash + STI yoy ≥ 1.5x CRVO's -23.62%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.27%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-32.53%
≥ 1.5x CRVO's -20.02%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-2.15%
Below half CRVO's -10.07%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
Less than half of CRVO's -21.64%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.56%
1.25-1.5x CRVO's -1.27%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
≥ 1.5x CRVO's -12.66%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-12.11%
Less than half of CRVO's -47.64%. David Dodd sees a more disciplined AP approach or lower volume.
-29.66%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
100.00%
Less than half of CRVO's -68.33%. David Dodd sees fewer expansions in other current obligations.
-11.86%
Less than half of CRVO's -25.25%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
-7.08%
Less than half of CRVO's -17.13%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-11.32%
50-75% of CRVO's -20.64%. Bruce Berkowitz notes a lower yoy liability increase.
6.25%
Above 1.5x CRVO's 3.36%. Michael Burry suspects heavy new equity expansion or dilution.
-2.72%
Similar yoy to CRVO's -2.79%. Walter Schloss sees parallel earnings retention vs. competitor.
100.00%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-46.50%
≥ 1.5x CRVO's -11.09%. David Dodd sees stronger capital base growth than competitor.
-28.33%
≥ 1.5x CRVO's -12.66%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.76%
Similar yoy changes to CRVO's -9.43%. Walter Schloss notes parallel total debt strategies.
40.72%
Above 1.5x CRVO's 23.87%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.